Methods are provided for separating magnetically responsive beads from a droplet in a droplet actuator. Droplet operations electrodes and a magnet are arranged in a droplet actuator to manipulate a bead-containing droplet and position it relative to a magnetic field region that attracts the magnetically responsive beads. The droplet operations electrodes are operated to control the droplet shape and transport it away from the magnetic field region to form a concentration of beads in the droplet. The continued transport of the droplet away from the magnetic field causes the concentration of beads to break away from the droplet to yield a small, concentrated bead-containing droplet immobilized by the magnet.

Methods are provided for separating magnetically responsive beads from a droplet in a droplet actuator. Droplet operations electrodes and a magnet are arranged in a droplet actuator to manipulate a bead-containing droplet and position it relative to a magnetic field region that attracts the magnetically responsive beads. The droplet operations electrodes are operated to control the droplet shape and transport it away from the magnetic field region to form a concentration of beads in the droplet. The continued transport of the droplet away from the magnetic field causes the concentration of beads to break away from the droplet to yield a small, concentrated bead-containing droplet immobilized by the magnet.

Devices and methods for characterization of samples are provided. Samples may comprise one or more analytes. Some methods described herein include performing enrichment steps on a device. Some methods described herein include performing mobilization of analytes. Analytes may then be further processed and characterized.

The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.

The present application relates to a kit for diagnosing pancreatic cancer, a method for providing information for diagnosing pancreatic cancer using the kit, and a method for diagnosing pancreatic cancer using same, wherein the kit includes an antibody specifically binding to complement factor B protein and an antibody specifically binding to carbohydrate antigen 19-9 protein. According to the present application, it is possible to provide a marker for diagnosing pancreatic cancer having enhanced sensitivity and specificity.

Lateral flow immunoassay devices for determining the concentration of an analyte in a sample and methods for measuring analyte concentration in sample using such lateral flow immunoassay devices.

Lateral flow immunoassay devices for determining the concentration of an analyte in a sample and methods for measuring analyte concentration in sample using such lateral flow immunoassay devices.

The invention provides a method detecting free light chains (FLCs) comprising: (i) providing a sample from a subject; (ii) mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii) passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv) detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.

The invention provides a method detecting free light chains (FLCs) comprising: (i) providing a sample from a subject; (ii) mixing the sample with an anti-FLC specific antibody, or fragments thereof capable of specifically binding the FLC, to form a mixture; (iii) passing the mixture through a capillary tube by capillary zone electrophoresis (CZE); and (iv) detecting the presence of the antibody or fragment thereof after passage through at least a portion of the capillary tube. Capillary tubes for use in CZE and kits comprising capilliary tubes and at least one anti-FLC antibody are also provided.

The present invention relates to use of an Anaplasma phagocytophilum protein APH1384 as diagnostic antigen for granulocytic anaplasmosis. The protein can remedy the drawback of missed detection of an existing diagnostic antigen P44 for granulocytic anaplasmosis, improve sensitivity of detection for granulocytic anaplasmosis, and facilitate rapid and accurate clinical diagnosis of granulocytic anaplasmosis.